Vir Biotechnology, Inc. (VIR) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1244494,
    "name": "Vir Biotechnology, Inc.",
    "stock_name": "Vir Biotechnology, Inc.",
    "full_name": "Vir Biotechnology, Inc.",
    "name_url": "stocks-analysis/vir-biotechnology-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "6.50",
    "chg": -0.28,
    "chgp": "-4.13%",
    "dir": -1,
    "prev_price": "6.78",
    "mcapval": "720.98",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US92764N1028",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "3.74 M",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/vir-biotechnology-inc-1244494-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Vir Biotechnology Hits Day Low of $5.87 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vir-biotechnology-hits-day-low-of-587-amid-price-pressure-3659313",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/VirBiotechnolog_priceRelatedfactors_3659313.png",
        "date": "2025-10-30 19:30:26",
        "description": "Vir Biotechnology, Inc. has faced notable challenges, with a significant stock decline and ongoing financial struggles, including a net profit drop and negative cash flow. Over the past three years, the company has underperformed compared to the S&P 500, leading to reduced stakeholder confidence and a small-cap market capitalization."
      },
      {
        "title": "Vir Biotechnology, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vir-biotechnologys-technical-trend-shifts-from-mildly-bearish-to-sideways-amid-stock-price-increase-3649037",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/VirBiotechnolog_technicaldot_3649037.png",
        "date": "2025-10-27 15:49:09",
        "description": "Vir Biotechnology, Inc. has recently revised its evaluation amid fluctuating market conditions. The stock, currently priced at $5.98, has shown significant volatility over the past year, with a 52-week high of $14.45 and a low of $4.16. Its performance has lagged behind the S&P 500 over various timeframes."
      },
      {
        "title": "Is Vir Biotechnology, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-vir-biotechnology-inc-technically-bullish-or-bearish-3547628",
        "imagepath": "",
        "date": "2025-09-20 19:59:38",
        "description": "As of 18 August 2025, the technical trend for Vir Biotechnology, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly MACD and KST show a mildly bullish signal. The Bollinger Bands are bullish on the weekly but mildly bearish on the monthly, suggesting mixed signals. \n\nIn terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a year-to-date return of -29.43% compared to the S&P 500's 12.22%, and a one-year return of -33.59% versus 17.14% for the benchmark...."
      },
      {
        "title": "Is Vir Biotechnology, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-vir-biotechnology-inc-overvalued-or-undervalued-3543947",
        "imagepath": "",
        "date": "2025-09-20 18:33:26",
        "description": "As of 4 May 2023, the valuation grade for Vir Biotechnology, Inc. has moved from expensive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued based on its current metrics, particularly given its negative P/E ratio and a Price to Book Value of 0.72, which suggests that the stock is trading below its book value. Additionally, the EV to EBITDA ratio stands at 0.23, further reinforcing the notion of overvaluation in comparison to its peers.\n\nIn the peer comparison, Maravai Lifesciences Holdings, Inc. has a significantly higher EV to EBITDA ratio of -15.5085, while Zentalis Pharmaceuticals, Inc. shows a more favorable EV to EBITDA of 1.0769, indicating that Vir Biotechnology is lagging behind its competitors. The company's recent stock performance has been disappointing, with a year-to-date return of -29.43% compared to the S&P 500's 12.22%, and a stag..."
      }
    ],
    "total": 9,
    "sid": "1244494",
    "stock_news_url": "https://www.marketsmojo.com/news/vir-biotechnology-inc-1244494"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Vir Biotechnology Hits Day Low of $5.87 Amid Price Pressure

2025-10-30 19:30:26

Vir Biotechnology, Inc. has faced notable challenges, with a significant stock decline and ongoing financial struggles, including a net profit drop and negative cash flow. Over the past three years, the company has underperformed compared to the S&P 500, leading to reduced stakeholder confidence and a small-cap market capitalization.

Vir Biotechnology, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics

2025-10-27 15:49:09

Vir Biotechnology, Inc. has recently revised its evaluation amid fluctuating market conditions. The stock, currently priced at $5.98, has shown significant volatility over the past year, with a 52-week high of $14.45 and a low of $4.16. Its performance has lagged behind the S&P 500 over various timeframes.

Is Vir Biotechnology, Inc. technically bullish or bearish?

2025-09-20 19:59:38

As of 18 August 2025, the technical trend for Vir Biotechnology, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly MACD and KST show a mildly bullish signal. The Bollinger Bands are bullish on the weekly but mildly bearish on the monthly, suggesting mixed signals. In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a year-to-date return of -29.43% compared to the S&P 500's 12.22%, and a one-year return of -33.59% versus 17.14% for the benchmark....

Is Vir Biotechnology, Inc. overvalued or undervalued?

2025-09-20 18:33:26

As of 4 May 2023, the valuation grade for Vir Biotechnology, Inc. has moved from expensive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued based on its current metrics, particularly given its negative P/E ratio and a Price to Book Value of 0.72, which suggests that the stock is trading below its book value. Additionally, the EV to EBITDA ratio stands at 0.23, further reinforcing the notion of overvaluation in comparison to its peers. In the peer comparison, Maravai Lifesciences Holdings, Inc. has a significantly higher EV to EBITDA ratio of -15.5085, while Zentalis Pharmaceuticals, Inc. shows a more favorable EV to EBITDA of 1.0769, indicating that Vir Biotechnology is lagging behind its competitors. The company's recent stock performance has been disappointing, with a year-to-date return of -29.43% compared to the S&P 500's 12.22%, and a stag...

View All News